John P. Connolly
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
John P. Connolly has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Aakash Mahant Mahant
Department of Microbiology-Immunology, Albert Einstein College of Medicine, Bronx, NY 10461, USA
1 shared publication Agnes Colanta
Department of Pathology, Albert Einstein College of Medicine , Bronx, New York
1 shared publicationAntonio Cajigas
Department of Pathology, Albert Einstein College of Medicine , Bronx, New York
1 shared publication- Betsy C. Herold
Division of Pediatric Infectious Diseases at the Children’s Hospital at Montefiore and the Albert Einstein College Medicine
1 shared publication - Deborah Ruth Gustafson
Department of Neurology, State University of New York Downstate Health Sciences University, Brooklyn, NY, USA
1 shared publication - Hayley Estrella
Drexel University College of Medicine , Philadelphia, Pennsylvania
1 shared publication
Latest Publications
- Open Access
- 8 December 2025
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 82 (4) , e710-e719
Impact of Vaginal Estradiol on the Genitourinary Syndrome of Menopause, Vaginal Microbiome and Mucosal Immune Mediators in Women Living With HIV
Background: Women with human immunodeficiency virus (HIV, WWH) experience early onset menopause and symptoms may impact antiretroviral therapy (ART) adherence. Vaginal estradiol is safe and effective for treatment of the genitourinary syndrome of menopause (GSM) but has not been studied in WWH. The study objective was to test whether vaginal estradiol would improve GSM symptoms in menopausal WWH. Methods: Menopausal WWH were randomized 1:1 to 12 weeks of open-label vaginal estradiol (n = 25) versus no treatment (n = 26). Participants had at least 1 GSM vulvovaginal symptom in the month prior (dryness, itching, irritation, soreness, or dyspareunia) and clinical atrophy. The primary outcome was difference in mean symptom severity (scale 0–3) defined by the composite vaginal symptom index (VSI) between baseline and week 12. Changes in severity of participants’ most bothersome symptom (MBS), vaginal maturation index (VMI), vaginal microbiome, and mucosal immune mediators were assessed. Results were compared by paired t test or Wilcoxon signed rank tests; a mixed effect model examined differences in VSI improvement between groups. Results: Mean age was 59 years, 78% self-reported as Black, and all were on ART. Both groups had significant reductions in VSI, however the magnitude was significantly greater in the estradiol group (P < .0001). Estradiol and younger age were associated with VSI improvement. VMI and MBS improved significantly only in the estradiol group. There were no significant changes in the microbiome or mucosal mediators. Conclusions: The favorable response to estradiol suggests that treatment perhaps initiated earlier may be beneficial for GSM in WWH and should be studied in larger clinical trials.
- 8 December 2025
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 82 (4) , e710-e719
Open AccessImpact of Vaginal Estradiol on the Genitourinary Syndrome of Menopause, Vaginal Microbiome and Mucosal Immune Mediators in Women Living With HIV
Background: Women with human immunodeficiency virus (HIV, WWH) experience early onset menopause and symptoms may impact antiretroviral therapy (ART) adherence. Vaginal estradiol is safe and effective for treatment of the genitourinary syndrome of menopause (GSM) but has not been studied in WWH. The study objective was to test whether vaginal estradiol would improve GSM symptoms in menopausal WWH. Methods: Menopausal WWH were randomized 1:1 to 12 weeks of open-label vaginal estradiol (n = 25) versus no treatment (n = 26). Participants had at least 1 GSM vulvovaginal symptom in the month prior (dryness, itching, irritation, soreness, or dyspareunia) and clinical atrophy. The primary outcome was difference in mean symptom severity (scale 0–3) defined by the composite vaginal symptom index (VSI) between baseline and week 12. Changes in severity of participants’ most bothersome symptom (MBS), vaginal maturation index (VMI), vaginal microbiome, and mucosal immune mediators were assessed. Results were compared by paired t test or Wilcoxon signed rank tests; a mixed effect model examined differences in VSI improvement between groups. Results: Mean age was 59 years, 78% self-reported as Black, and all were on ART. Both groups had significant reductions in VSI, however the magnitude was significantly greater in the estradiol group (P < .0001). Estradiol and younger age were associated with VSI improvement. VMI and MBS improved significantly only in the estradiol group. There were no significant changes in the microbiome or mucosal mediators. Conclusions: The favorable response to estradiol suggests that treatment perhaps initiated earlier may be beneficial for GSM in WWH and should be studied in larger clinical trials.
- Open Access
- 9 April 2025
- Published by American Society for Microbiology in mBio
- Vol. 16 (4) , e0298924
The physical biogeography of Fusobacterium nucleatum in health and disease
Fusobacterium nucleatum ( Fn ) is an oral commensal inhabiting the human gingival plaque that is rarely found in the gut. However, in colorectal cancer (CRC), Fn can be isolated from stool samples and detected in metagenomes. We hypothesized that ecological characteristics of the gut are altered by disease, enabling Fn to colonize. Multiple genomically distinct populations of Fn exist, but their ecological preferences are unstudied. We identified six well-separated populations in 133 Fn genomes and used simulated metagenomes to demonstrate sensitive detection of populations in human oral and gut metagenomes. In 9,560 samples from 11 studies, Fn population C2 animalis is elevated in gut metagenomes from CRC and Crohn's disease patients and is observed more frequently in CRC stool samples than in the gingiva. Polymorphum, the most prevalent gingival Fn population, is significantly increased in Crohn's stool samples; this effect was significantly stronger in male hosts than in female. We find polymorphum genomes are enriched for biosynthetic gene clusters and fluoride exporters, while C2 animalis are high in iron transporters. Fn populations thus associate with specific clinical and demographic phenotypes and harbor distinct functional features. Ecological differences in closely related groups of bacteria inform microbiome impacts on human health. IMPORTANCE: Fusobacterium nucleatum is a bacterium normally found in the gingiva. F. nucleatum generally does not colonize the healthy gut, but is observed in approximately a third of colorectal cancer (CRC) patient guts. F. nucleatum 's presence in the gut during CRC has been linked to worse prognosis and increased tumor proliferation. Here, we describe the population structure of F. nucleatum in oral and gut microbiomes. We report substantial diversity in gene carriage among six distinct populations of F. nucleatum and identify population disease and body-site preferences. We find the C2 animalis population is more common in the CRC gut than in the gingiva and is enriched for iron transporters, which support gut colonization in known pathogens. We find that C2 animalis is also enriched in Crohn's disease and type 2 diabetes, suggesting ecological commonalities between the three diseases. Our work shows that closely related bacteria can have different associations with human physiology.
- 9 April 2025
- Published by American Society for Microbiology in mBio
- Vol. 16 (4) , e0298924
Open AccessThe physical biogeography of Fusobacterium nucleatum in health and disease
Fusobacterium nucleatum ( Fn ) is an oral commensal inhabiting the human gingival plaque that is rarely found in the gut. However, in colorectal cancer (CRC), Fn can be isolated from stool samples and detected in metagenomes. We hypothesized that ecological characteristics of the gut are altered by disease, enabling Fn to colonize. Multiple genomically distinct populations of Fn exist, but their ecological preferences are unstudied. We identified six well-separated populations in 133 Fn genomes and used simulated metagenomes to demonstrate sensitive detection of populations in human oral and gut metagenomes. In 9,560 samples from 11 studies, Fn population C2 animalis is elevated in gut metagenomes from CRC and Crohn's disease patients and is observed more frequently in CRC stool samples than in the gingiva. Polymorphum, the most prevalent gingival Fn population, is significantly increased in Crohn's stool samples; this effect was significantly stronger in male hosts than in female. We find polymorphum genomes are enriched for biosynthetic gene clusters and fluoride exporters, while C2 animalis are high in iron transporters. Fn populations thus associate with specific clinical and demographic phenotypes and harbor distinct functional features. Ecological differences in closely related groups of bacteria inform microbiome impacts on human health. IMPORTANCE: Fusobacterium nucleatum is a bacterium normally found in the gingiva. F. nucleatum generally does not colonize the healthy gut, but is observed in approximately a third of colorectal cancer (CRC) patient guts. F. nucleatum 's presence in the gut during CRC has been linked to worse prognosis and increased tumor proliferation. Here, we describe the population structure of F. nucleatum in oral and gut microbiomes. We report substantial diversity in gene carriage among six distinct populations of F. nucleatum and identify population disease and body-site preferences. We find the C2 animalis population is more common in the CRC gut than in the gingiva and is enriched for iron transporters, which support gut colonization in known pathogens. We find that C2 animalis is also enriched in Crohn's disease and type 2 diabetes, suggesting ecological commonalities between the three diseases. Our work shows that closely related bacteria can have different associations with human physiology.